Compare TY & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TY | GENB |
|---|---|---|
| Founded | 1929 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | TY | GENB |
|---|---|---|
| Price | $34.83 | $16.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 34.4K | ★ 886.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.58 |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.53 | $11.00 |
| 52 Week High | $36.03 | $17.42 |
| Indicator | TY | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 62.89 |
| Support Level | $34.20 | $11.73 |
| Resistance Level | $34.79 | $16.75 |
| Average True Range (ATR) | 0.64 | 1.02 |
| MACD | -0.07 | 0.36 |
| Stochastic Oscillator | 28.68 | 78.29 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.